Gain Therapeutics (GANX) Debt to Equity (2020 - 2025)
Gain Therapeutics has reported Debt to Equity over the past 6 years, most recently at $0.07 for Q3 2025.
- Quarterly results put Debt to Equity at $0.07 for Q3 2025, up 29.4% from a year ago — trailing twelve months through Sep 2025 was $0.07 (up 29.4% YoY), and the annual figure for FY2024 was $0.06, up 32.34%.
- Debt to Equity for Q3 2025 was $0.07 at Gain Therapeutics, down from $0.12 in the prior quarter.
- Over the last five years, Debt to Equity for GANX hit a ceiling of $0.12 in Q2 2025 and a floor of $0.02 in Q1 2021.
- Median Debt to Equity over the past 5 years was $0.04 (2024), compared with a mean of $0.05.
- Biggest five-year swings in Debt to Equity: plummeted 83.25% in 2021 and later surged 195.95% in 2025.
- Gain Therapeutics' Debt to Equity stood at $0.02 in 2021, then soared by 60.27% to $0.03 in 2022, then skyrocketed by 41.26% to $0.05 in 2023, then soared by 32.34% to $0.06 in 2024, then rose by 20.19% to $0.07 in 2025.
- The last three reported values for Debt to Equity were $0.07 (Q3 2025), $0.12 (Q2 2025), and $0.07 (Q1 2025) per Business Quant data.